Skip to main content
NOVAVAX INC logo

NOVAVAX INC — Investor Relations & Filings

Ticker · NVAX ISIN · US6700024010 LEI · 529900J4GJHPEPQ23205 US Manufacturing
Open in API
Filings indexed 1,095 across all filing types
Latest filing 2020-02-12 Major Shareholding Noti…
Country US United States of America
Listing US NVAX

About NOVAVAX INC

https://www.novavax.com/?locale=US

Novavax Inc. is a biotechnology company that develops and commercializes vaccines to prevent serious infectious diseases. The company utilizes a proprietary, protein-based vaccine technology platform, which includes its novel Matrix-M™ adjuvant, to create its vaccine candidates. Its primary commercial product is a protein-based COVID-19 vaccine, Nuvaxovid™. Novavax's research and development pipeline is focused on addressing significant health needs, including influenza and a combination COVID-19-influenza vaccine. The company's strategy emphasizes advancing its pipeline assets and establishing strategic partnerships to maximize the global health impact of its technology.

Recent filings

Filing Released Lang Actions
SCHEDULE 13G/A
Major Shareholding Notification
2020-02-12 English
Major Shareholding Notification 2020
Major Shareholding Notification
2020-02-10 English
FORM 4 SUBMISSION
Director's Dealing
2020-02-04 English
FORM 8-K
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The content describes the filing of a prospectus supplement for an at-the-market offering of common stock, including the sales agreement and legal opinion exhibits. This is an update on the company's capital raising activities, specifically a financing update. The document is not a full financial report, earnings release, or management discussion, but rather a notice of a capital/financing event. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length is under 5,000 characters, but it contains substantive information about the financing agreement, not just an announcement of a report publication, so it is not RPA or RNS.
2020-01-21 English
424B5
Capital/Financing Update Classification · 95% confidence The document is a prospectus supplement filed pursuant to SEC rules, specifically a 424B5 filing, which relates to the issuance and sale of common stock by Novavax, Inc. It details the terms of an 'at the market offering' of up to $100 million of common stock, including use of proceeds, dilution, risk factors, and plan of distribution. This type of document is a capital raising disclosure and update on financing activities rather than a financial report, earnings release, or management discussion. It is not an annual or quarterly report, nor a proxy or governance document. The presence of terms like 'prospectus supplement', 'sales agreement', 'offering', 'use of proceeds', and 'dilution' clearly indicate this is a Capital/Financing Update. Therefore, the correct classification is Capital/Financing Update (CAP). The document length and detail support a high confidence level.
2020-01-21 English
Regulatory Filings 2020
Regulatory Filings
2020-01-10 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.